Jump to content
  • Sign Up
Scott Adams

Biolinerx Completes Dose Escalation Stage Of Phase 1/2 Study For Novel ... - Marketwatch

Rate this topic

Recommended Posts

BioLineRx Completes Dose Escalation Stage of Phase 1/2 Study for Novel ...

MarketWatch

“BL-7010 for the treatment of celiac disease is one of our lead development programs, and we are very happy to see that it is safe and well tolerated - even at very high doses that are significantly above the expected clinical efficacious dose,” said ...

BioLineRx: BL-7010 Completes Dose-escalation Stage Of Phase 1/2 Study NASDAQ

all 2 news articles »

View the full article

Share this post


Link to post
Share on other sites

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.

Guest
Reply to this topic...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.


×
×
  • Create New...